Crinetics Pharmaceuticals News and Activities

Crinetics Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Crinetics Pharmaceuticals is a company listed under the stock ticker CRNX (US).

View the org chart displaying its 33 main executives

Most searched biographies at Crinetics Pharmaceuticals

• Scott Struthers, Chief Executive Officer and Director
• Camille Bedrosian, Director
• Wendell Wierenga, Chairman of the Board

Popular executive movements at Crinetics Pharmaceuticals

• Jeff Knight, Chief Operating Officer, will leave the company on Apr. 10, 2026  (posted on March 24 2026).

Create your alert
to follow the executive moves at Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Crinetics Pharmaceuticals

• Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
• Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
• Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
• News & Events
• News & Events
• Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
• Crinetics Pharmaceuticals Press Releases - Read Our Latest
• Crinetics Pharmaceuticals Press Releases - Read Our Latest
• Crinetics Pharmaceuticals Press Releases - Read Our Latest
• Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism - Crinetics Pharmaceuticals
• View more press releases Close

Social media about Crinetics Pharmaceuticals

• Crinetics Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Crinetics Pharmaceuticals on LinkedIn, X (Twitter) & YouTube